Premium
EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders
Author(s) -
Boyman O.,
Kaegi C.,
Akdis M.,
Bavbek S.,
Bossios A.,
Chatzipetrou A.,
Eiwegger T.,
Firinu D.,
Harr T.,
Knol E.,
Matucci A.,
Palomares O.,
SchmidtWeber C.,
Simon H.U.,
Steiner U. C.,
Vultaggio A.,
Akdis C. A.,
Spertini F.
Publication year - 2015
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.12616
Subject(s) - thymic stromal lymphopoietin , immunology , medicine , allergy , cytokine , immune system , chemokine receptor , chemokine , tumor necrosis factor alpha
Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by living organisms and directed against a specific determinant, for example, a cytokine or receptor. In inflammatory and autoimmune diseases, biologicals have revolutionized the treatment of several immune‐mediated disorders. Biologicals have also been tested in allergic disorders. These include agents targeting IgE; T helper 2 (Th2)‐type and Th2‐promoting cytokines, including interleukin‐4 ( IL ‐4), IL ‐5, IL ‐9, IL ‐13, IL ‐31, and thymic stromal lymphopoietin ( TSLP ); pro‐inflammatory cytokines, such as IL ‐1β, IL ‐12, IL ‐17A, IL ‐17F, IL ‐23, and tumor necrosis factor ( TNF ); chemokine receptor CCR 4; and lymphocyte surface and adhesion molecules, including CD 2, CD 11a, CD 20, CD 25, CD 52, and OX 40 ligand. In this task force paper of the Interest Group on Biologicals of the European Academy of Allergy and Clinical Immunology, we review biologicals that are currently available or tested for the use in various allergic and urticarial pathologies, by providing an overview on their state of development, area of use, adverse events, and future research directions.